WST
West Pharmaceutical Services, Inc.
WST
West Pharmaceutical Services, Inc.
NOBL is outperforming SPY YTD in 2026, returning 12.9% versus SPY's 7.88%, with 45 Aristocrats ahead of SPY. Dividend growth among Aristocrats in 2026 averages 4.10%, with recent increases from ALB, F
West Pharmaceutical Services delivered a strong 2Q26, beating on both revenue ($872.3M, +13.8% YoY) and EPS ($2.37, +$0.29 vs. consensus). WST raised full-year guidance to $3.345–$3.380B in sales and
West Pharmaceutical Services NYSE: WST raised its full-year 2026 outlook after reporting second-quarter results that topped management's expectations, supported by strong demand for high-value product